Advertisement
Canada markets open in 4 hours 31 minutes
  • S&P/TSX

    21,885.38
    +11.66 (+0.05%)
     
  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     
  • DOW

    38,085.80
    -375.12 (-0.98%)
     
  • CAD/USD

    0.7329
    +0.0006 (+0.08%)
     
  • CRUDE OIL

    83.73
    +0.16 (+0.19%)
     
  • Bitcoin CAD

    87,875.19
    +739.15 (+0.85%)
     
  • CMC Crypto 200

    1,389.78
    -6.76 (-0.48%)
     
  • GOLD FUTURES

    2,360.50
    +18.00 (+0.77%)
     
  • RUSSELL 2000

    1,981.12
    -14.31 (-0.72%)
     
  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     
  • NASDAQ futures

    17,742.25
    +174.75 (+0.99%)
     
  • VOLATILITY

    15.54
    +0.17 (+1.11%)
     
  • FTSE

    8,106.26
    +27.40 (+0.34%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • CAD/EUR

    0.6820
    -0.0001 (-0.01%)
     

Booming European CBD Sales Signal a New Potentially Multi-Billion-Dollar Market

Thanks to a trending new use as a tobacco substitute cannabidiol (CBD) sales are exploding across Europe. According to research firm Brightfield Group, European CBD sales will surge by more than five times to reach nearly US$1.7 billion in 2023, further boosting interest in CBD-producing companies, including MYM Nutraceuticals Inc. (CSE:MYM) (OTC:MYMMF), CV Sciences Inc. (OTC:CVSI), Curaleaf Holdings, Inc. (CSE:CURA) (OTC:CURLF), Tilray, Inc. (NASDAQ:TLRY), and Green Growth Brands Inc. (CSE:GGB) (OTC:GGBXF). Globally, Brightfield Group has also projected CBD sales to hit US$22 billion by 2022. This potential gave rise to North American companies looking for global opportunities, such as MYM Nutraceuticals Inc. (CSE:MYM) (OTC:MYMMF) who announced three new international CBD-rich projects over the last 6 weeks. Starting in late March, MYM increased its stake in Colombia Organica to 80%. The project includes 3 licenses, which involve the production of cannabis derivatives, and cultivation of both psychoactive (THC) and non-psychoactive (CBD) cannabis. MYM followed up with ... Click here to view full article